RSV Respiratory syncytial virus

RSV: The Disease and Pipeline Vaccines

Despite effectiveness and safety issues, a vaccine targeting Respiratory Syncytial Virus (RSV) by GlaxoSmithKline Biologicals (GSK) was approved by the FDA on May 3, 2023 for people ages 60 and older, and now Pfizer’s RSV vaccine targeting pregnant women is moving through the perfunctory steps of captured federal agencies on it’s way to licensing.


‘Sad Day for Babies and Mums’: FDA Panel Recommends Pfizer’s RSV Vaccine for Pregnant Women

Advisers to the U.S. Food and Drug Administration on Thursday recommended the agency approve Pfizer’s respiratory syncytial virus, or RSV, vaccine for pregnant women, despite concerns about premature births identified during clinical trials.

Prepare to be bombarded by marketing messages and pressure from doctors and nurses, who will be unaware of the concerns raised in the clinical trials, the lack of longterm safety studies, or the potential for unintended consequences of the use of the products. Educate yourself on the history of the transitory infection, the factors that increase susceptibility to severe disease, the nutrient and natural prevention and treatment options, naturally acquired immunity, and passive immunity from mother to child.

If you don’t already have a trusted health care provider aligned with your approach to health and wellness, interview health care providers until you find one to serve your needs.



What is the History of Respiratory Syncytial Virus (RSV) infection in the U.S. and other countries?
“Respiratory Syncytial Virus (RSV) was initially identified in 1955 by JA Morris in laboratory chimpanzees housed at Walter Reed Army Institute of Research in Maryland. The chimpanzees, which were used in polio vaccine research, exhibited symptoms of respiratory illness. Morris was able to confirm that the viral agent, which was initially named Chimpanzee Coryza Agent (CCA), was contagious when he exposed a second group of chimpanzees to the infection” . . . READ MORE.

From Chimpanzees to Children: The Origins of RSV — Respiratory Syncytial Virus


From the FLCCC Alliance:


Download I-CARE RSV and Flu Protocol

A Guide to Diagnosing and Managing Influenza and Respiratory Syncytial Virus (RSV) Infections in Adults
In adult patients, COVID-19 (Omicron variant), influenza, and RSV present with similar symptoms and can, therefore, be difficult to distinguish. This guide aims to help diagnose and treat Influenza and Respiratory Syncytial Virus (RSV).

For advice on how to protect yourself against infection, see I-PREVENT: COVID, Flu and RSV Protection Protocol. For treatment of COVID-19, see I-CARE: Early COVID Treatment Protocol.

BOOK: A Holistic Approach to Viruses by Dr. David Brownstein